Roche to buy US gene therapy group Spark for $4.3 bn

Swiss pharmaceuticals giant Roche said Monday it reached a deal worth $4.3 billion (3.7 billion euros) to buy US group Spark Therapeutics, which specialises in the development of gene therapy drugs. Roche said the deal was approved by the boards of both companies, offering $114.50 a share, a premium to…

RNA proofreading mistakes drive group of autoimmune diseases

A team from Scripps Research has found a molecular cause of a group of rare autoimmune disorders in which the immune system attacks the body’s own healthy cells. The discovery, published Dec. 18 in Nature Communications, improves understanding of a protein’s role in several autoimmune disorders, including Singleton-Merten syndrome (SMS),…